Evidence map›Paper›PMID 34255936›Full record

ArticleCancer reports (Hoboken, N.J.)2022

Predictive factors of acute respiratory events during initial induction chemotherapy in patients with advanced neuroblastoma.

Motohiro Matsui, Atsushi Makimoto, Nobuhiro Nishio, Yoshiyuki Takahashi, Mitsuyoshi Urashima, Yuki Yuza

Abstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Motohiro MatsuiDepartment of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.ORCID 0000-0002-3651-0737
Atsushi MakimotoDepartment of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.ORCID 0000-0002-0036-7748
Nobuhiro NishioDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshiyuki TakahashiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mitsuyoshi UrashimaDivision of Molecular Epidemiology, Jikei University School of Medicine, Tokyo, Japan.
Yuki YuzaDepartment of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute respiratory events (ARE) occasionally occur during induction chemotherapy as a complication in patients with advanced neuroblastoma.

aimsThe present study aimed to identify the predictive factors of ARE, defined as severe hypoxia, during initial induction chemotherapy in patients with newly diagnosed advanced neuroblastoma. METHODS AND

resultsThe medical records of 75 consecutive patients in whom stage III or IV neuroblastoma was newly diagnosed between January 2003 and December 2018 at two medical institutions were retrospectively reviewed. The outcome was ARE, which were assessed by measuring oxygen saturation between days 1 and 14 of initial induction chemotherapy. Severe hypoxia was defined as grade 3 or higher according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE v4.0) or decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO

conclusionThe LDH value and DIC score on admission may be clinically useful predictors of ARE during initial induction chemotherapy in patients with advanced neuroblastoma.

Indexed as

Disseminated Intravascular CoagulationNeuroblastomaHumansHypoxiaInduction ChemotherapyRetrospective Studiesacute respiratory distress syndromeacute respiratory eventsdisseminated intravascular coagulation (DIC) scorelactate dehydrogenase (LDH)neuroblastoma

Identifiers

PMID34255936
PMCPMC9124507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.